In summation, these authors determined that, considering the average half-life duration of brolucizumab, its use in the case of AMD can be insufficient to inhibit VEGF expression when used every 12 weeks, in comparison to aflibercept [44]. Here, VEGFA is linked to age-related macular degeneration.